Inhaled Reliever Therapies for Asthma
JAMA · 14.01.2025 · 333 (2) · 143
DOI: 10.1001/jama.2024.22700 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, erschienen am 14.01.2025. Verfasst von Daniel G Rayner und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Adrenal Cortex Hormones, Adrenergic beta-2 Receptor Agonists, Anti-Asthmatic Agents, Asthma. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Importance The optimal inhaled reliever therapy for asthma remains unclear.
Objective
To compare short-acting β agonists (SABA) alone with SABA combined with inhaled corticosteroids (ICS) and with the fast-onset, long-acting β agonist formoterol combined with ICS for asthma. Data Sources The MEDLINE, Embase, and CENTRAL databases were searched from January 1, 2020, to September 27, 2024, without language restrictions. Study Selection Pairs of reviewers independently selected randomized clinical trials evaluating (1) SABA alone, (2) ICS with formoterol, and (3) ICS with SABA (combined or separate inhalers). Data Extraction and Synthesis Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analyses synthesized outcomes. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to evaluate the certainty of evidence. Main Outcomes and Measures Asthma symptom control (5-item Asthma Control Questionnaire; range, 0-6, lower scores indicate better asthma control; minimum important difference [MID], 0.5 points), asthma-related quality of life (Asthma Quality of Life Questionnaire; range, 1-7, higher scores indicate better quality of life; MID, 0.5 points), risk of severe exacerbations, and risk of serious adverse events.
Results
A total of 27 randomized clinical trials (N = 50 496 adult and pediatric patients; mean age, 41.0 years; 20 288 male [40%]) were included. Compared with SABA alone, both ICS-containing relievers were associated with fewer severe exacerbations (ICS-formoterol risk ratio [RR], 0.65 [95% CI, 0.60-0.72]; risk difference [RD], −10.3% [95% CI, −11.8% to −8.3%]; ICS-SABA RR, 0.84 [95% CI, 0.73-0.95]; RD, −4.7% [95% CI, −8.0% to −1.5%]) with high certainty. Compared with SABA alone, both ICS-containing relievers were associated with improved asthma control (ICS-formoterol RR improvement [MID] in total score, 1.07 [95% CI, 1.04-1.10]; RD, 4.1% [95% CI, 2.3%-5.9%]; ICS-SABA RR, 1.09 [95% CI, 1.03-1.15]; RD, 5.4% [95% CI, 1.8%-8.5%]) with high certainty. In an indirect comparison with ICS-SABA, ICS-formoterol was associated with fewer severe exacerbations (RR, 0.78 [95% CI, 0.66-0.92]; RD, −5.5% [95% CI, −8.4% to −2.0%]) with moderate certainty. Compared with SABA alone, ICS-formoterol (RD, −0.6% [95% CI, −1.3% to 0%]) was not associated with increased risk of serious adverse events (high certainty) and ICS-SABA (RD, 0% [95% CI, −1.1% to 1.2%]) was not associated with increased risk of serious adverse events (moderate certainty). Conclusions and Relevance In this network meta-analysis of patients with asthma, ICS combined with formoterol and ICS combined with SABA were each associated with reduced asthma exacerbations and improved asthma control compared with SABA alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Capital Allergy & Respiratory Disease Center, Sacramento, California.
- Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri.
- Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock.
- Department of Pediatrics, The University of Chicago, Chicago, Illinois.
Förderung
- NIMHD NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Rayner, D. G., Ferri, D. M., Guyatt, G. H., O'Byrne, P. M., Brignardello-Petersen, R., Foroutan, F., Chipps, B., Sumino, K., Perry, T. T., Nyenhuis, S., Oppenheimer, J., Israel, E., Hoyte, F., Rivera-Spoljaric, K., McCabe, E., Rangel, S., Shade, L. E., Press, V. G., Hall, L., …, & Chu, D. K. (2025). Inhaled Reliever Therapies for Asthma. JAMA, 333(2), 143. https://doi.org/10.1001/jama.2024.22700
Vancouver
Rayner DG, Ferri DM, Guyatt GH, O'Byrne PM, Brignardello-Petersen R, Foroutan F, et al. Inhaled Reliever Therapies for Asthma. JAMA. 2025;333(2):143. doi:10.1001/jama.2024.22700
BibTeX
@article{Rayner2025,
author = {Rayner, Daniel G and Ferri, Dario M and Guyatt, Gordon H and O'Byrne, Paul M and Brignardello-Petersen, Romina and Foroutan, Farid and Chipps, Bradley and Sumino, Kaharu and Perry, Tamara T and Nyenhuis, Sharmilee and Oppenheimer, John and Israel, Elliot and Hoyte, Flavia and Rivera-Spoljaric, Katherine and McCabe, Ellen and Rangel, Susana and Shade, Lindsay E and Press, Valerie G and Hall, Lisa and Sue-Wah-Sing, Dia and Melendez, Angel and Orr, Hilarry and Winders, Tonya and Gardner, Donna D and Przywara, Kathyrn and Rank, Matthew A and Bacharier, Leonard B and Mosnaim, Giselle and Chu, Derek K},
title = {Inhaled Reliever Therapies for Asthma},
journal = {JAMA},
year = {2025},
volume = {333},
number = {2},
pages = {143},
doi = {10.1001/jama.2024.22700}
}
EUVIMED